Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04035239 · ClinicalTrials.gov registry record · Phase 1

Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma

A Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Stanford University.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target
1
Study location

NCT04035239: Completed Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Stanford University.

NCT04035239 is a Phase 1 study of Glaucoma and Ocular Hypertension that has completed, run by Stanford University. The registered enrollment target is 11 participants, below the 911-participant average among 92 other Glaucoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04035239, a Phase 1 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

This is an open-label trial of 20 study participants with glaucoma or ocular hypertension. Participants with qualifying study eye(s) after screening and baseline evaluations will receive the Balance Goggles System. After a baseline evaluation (prior to negative pressure application through the BGS), study eyes will be treated for one hour in the clinic and be evaluated again. They will then use the BGS for the next 3-6 weeks and be evaluated again. The goal is to determine whether the intraocular pressure (IOP)-lowering effects of BGS is accompanied by changes in retinal thickness measured by optical coherence tomography (OCT), retinal vascular density measured by OCT-angiography, or retinal fluorescence measured by a fundus camera.

Primary Outcome

Change from baseline in retinal nerve fiber layer thickness measured by optical coherence tomography imaging

Interventions

  • DEVICE BGS goggles

Study Locations (1)

California

  • Byers Eye Institute at Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2019-07-23
Est. Completion 2022-03-28
Phase Phase 1
Stanford University

1,744 total trials

What the finished NCT04035239 record still lists

NCT04035239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 911-participant average among 92 other Glaucoma trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which BGS goggles is the first listed.

NCT04035239 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04035239 about?

NCT04035239 is a clinical study titled "Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma". This is an open-label trial of 20 study participants with glaucoma or ocular hypertension. Participants with qualifying study eye(s) after screening and baseline evaluations will receive the Balance Goggles System. After a baseline evaluation (prior to negative pressure application through the BGS),...

What is the current status of trial NCT04035239?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-07-23. Estimated completion is 2022-03-28.

What conditions does trial NCT04035239 study?

This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.

What interventions are being tested in trial NCT04035239?

The interventions under investigation include: BGS goggles (DEVICE).

Who is sponsoring clinical trial NCT04035239?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04035239 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04035239's enrollment target sits among peer trials

11 90th of 92 higher than 2 of 92 other Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04035239, the US trial registry maintained by the National Library of Medicine. NCT04035239 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.